12th Annual AACI CRI Meeting: Day 2 Overview

More than 1,000 cancer center clinical trial leaders and other colleagues registered for the two-day 12th Annual AACI CRI Meeting, held virtually this year due to travel and gathering restrictions caused by the COVID-19 pandemic. 

The second day of the meeting began with remarks from CRI Steering Committee Chair Dr. Theresa L. Werner, followed by information-rich presentations by this year’s three abstract winners, including an engaging Q&A session. Seventy-seven abstracts were submitted, focusing on solutions tested and implemented to address clinical research challenges that can impede cancer drug development. The abstract presenters were Kimberly Jenkins, Cleveland Clinic Cancer Center; Shirley Cheng, University of Hawai'i Cancer Center, University of Hawai'i at Mānoa; and Britni Secor, Mays Cancer Center, UT Health San Antonio. 

Seven honorable mention posters, one from each abstract category, were also presented by: Ryan Chiechi, City of Hope Comprehensive Cancer Center; Tiffany Cull, University of Colorado Cancer Center; Rachel Kingsford, Huntsman Cancer Institute, University of Utah; Maureen Kelley, Barbara Ann Karmanos Cancer Institute, Wayne State University; Dr. Victor Santana, Comprehensive Cancer Center, St. Jude Children's Research Hospital; Jaime Wurth, Masonic Cancer Center, University of Minnesota; and Caitlin Sanford, Memorial Sloan Kettering Cancer Center.

As in previous years, a session on NCI’s Cancer Center Support Grant (CCSG) was particularly popular. Alex Zafirovski, executive director of administration at Robert H. Lurie Comprehensive Cancer Center of Northwestern University, moderated the panel discussion and Dr. Carrie Lee talked about how her institution, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, met new expectations with the CCSG and prepared for a virtual site visit. 

The CCSG Q&A session featured Dr. Gisele Sarosy, NCI’s associate director for informatics and biomarkers, and Dr. Henry Ciolino, director of NCI’s Office of Cancer Centers. Some questions revolved around community outreach and engagement, including what might constitute "reasonable consideration" for accruing underserved populations to trials. NCI’s Clinical Trials Reporting Program (CTRP) was another area of interest, and Dr. Ciolino urged centers making their first application for NCI designation to focus on engaging with CTRP.

"Regulatory Work Simplified: Providing Higher Quality Service to Trial Sponsors" was the final presentation of the AACI CRI Annual Meeting. Jaclyn Clark, marketing manager for Complion, talked about the company’s eRegulatory document and workflow management platform.

Many thanks to the meeting’s corporate supporters who exhibited, presented, and otherwise participated in this event: Advarra, home of Forte Technology Solutions; ASCO; Complion; Essex Management; Florence, Huron; Merck; Novartis; and Veeva Systems. And thanks again to everyone who attended—virtually—the 12th Annual AACI CRI Meeting. We hope to see you in person in 2021!
Medical Arts Building
3708 Fifth Avenue, Suite 503
Pittsburgh, PA 15213